Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 drug interaction study with nintedanib and pirfenidone in healthy volunteers
NCT06070610Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nerandomilast, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 24 hours, Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 24 hours and 4 more. Started Nov 2023; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT06070610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070610.